Metilfenidato Tecnigen

Methylphenidate hydrochloride, the active ingredient in Metilfenidato Tecnigen, is a central nervous system stimulant presented as an oral formulation for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and narcolepsy in appropriate patient populations.

GNH USA supplies Metilfenidato Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metilfenidato Tecnigen is a central nervous system stimulant used in the management of specific neurobehavioral disorders. - Attention deficit hyperactivity disorder (ADHD) in children and adolescents: improves focus, reduces impulsivity and hyperactivity. - Attention deficit hyperactivity disorder (ADHD) in adults: enhances concentration and reduces distractibility. - Narcolepsy: decreases daytime sleepiness and improves wakefulness.

Methylphenidate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Irritability: increased emotional lability.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, tachycardia, or arrhythmia. - Psychosis: emergence of hallucinations or delusional thinking. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Priapism: prolonged, painful erection. - New or worsening tics: involuntary motor or vocal movements.

Before initiating therapy, clinicians should evaluate several safety considerations. - Assess cardiovascular status: obtain baseline blood pressure and heart rate. - Monitor growth in children: track height and weight regularly. - Avoid use in patients with known hypersensitivity to methylphenidate. - Use caution with psychiatric disorders: observe for mood swings or emergence of psychosis. - Store at room temperature: keep in the original container, protect from moisture and heat.

Methylphenidate can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Sympathomimetic agents (e.g., decongestants): may amplify cardiovascular effects. - Certain antipsychotics (e.g., haloperidol): can reduce stimulant efficacy.

Moderate Interactions (Monitor Closely):\n- Selective serotonin reuptake inhibitors (SSRIs): may increase risk of serotonin syndrome. - Antihypertensive drugs: possible attenuation of blood‑pressure‑lowering effect. - Alcohol: can enhance central nervous system stimulation and impair judgment.